AR013759A1 - Imidazotriazinonas sustituidas por 2-fenilo, procedimiento para su preparacion, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos - Google Patents

Imidazotriazinonas sustituidas por 2-fenilo, procedimiento para su preparacion, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos

Info

Publication number
AR013759A1
AR013759A1 ARP980105724A ARP980105724A AR013759A1 AR 013759 A1 AR013759 A1 AR 013759A1 AR P980105724 A ARP980105724 A AR P980105724A AR P980105724 A ARP980105724 A AR P980105724A AR 013759 A1 AR013759 A1 AR 013759A1
Authority
AR
Argentina
Prior art keywords
carbon atoms
linear
different
branched
preparation
Prior art date
Application number
ARP980105724A
Other languages
English (en)
Spanish (es)
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013759(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of AR013759A1 publication Critical patent/AR013759A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP980105724A 1997-11-12 1998-11-12 Imidazotriazinonas sustituidas por 2-fenilo, procedimiento para su preparacion, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos AR013759A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone

Publications (1)

Publication Number Publication Date
AR013759A1 true AR013759A1 (es) 2001-01-10

Family

ID=27217917

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980105724A AR013759A1 (es) 1997-11-12 1998-11-12 Imidazotriazinonas sustituidas por 2-fenilo, procedimiento para su preparacion, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos
ARP020101786A AR035972A2 (es) 1997-11-12 2002-05-15 Imidazotriazinonas sustituidas por 2- fenilo, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP020101786A AR035972A2 (es) 1997-11-12 2002-05-15 Imidazotriazinonas sustituidas por 2- fenilo, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos

Country Status (43)

Country Link
US (9) US6362178B1 (show.php)
EP (3) EP2295436A1 (show.php)
JP (2) JP3356428B2 (show.php)
KR (2) KR100430355B1 (show.php)
CN (2) CN1123573C (show.php)
AR (2) AR013759A1 (show.php)
AT (1) ATE213246T1 (show.php)
AU (1) AU738675B2 (show.php)
BG (1) BG65257B1 (show.php)
BR (2) BR9812785A (show.php)
CA (2) CA2395558C (show.php)
CH (1) CH693954A5 (show.php)
CO (1) CO4980861A1 (show.php)
CU (1) CU23063A3 (show.php)
CY (1) CY1112949T1 (show.php)
CZ (1) CZ301911B6 (show.php)
DE (3) DE59803108D1 (show.php)
DK (3) DK1049695T3 (show.php)
EE (1) EE04781B1 (show.php)
ES (3) ES2172945T3 (show.php)
FI (1) FI113772B (show.php)
GB (1) GB2346877B (show.php)
HN (1) HN1998000175A (show.php)
HR (2) HRP20000292B1 (show.php)
HU (3) HU230154B1 (show.php)
ID (1) ID25871A (show.php)
IL (3) IL135462A0 (show.php)
IN (1) IN188419B (show.php)
LU (1) LU90561B1 (show.php)
MY (1) MY138535A (show.php)
NO (2) NO314940B1 (show.php)
NZ (1) NZ504436A (show.php)
PE (1) PE131799A1 (show.php)
PL (2) PL194801B1 (show.php)
PT (2) PT1049695E (show.php)
SE (1) SE522809C2 (show.php)
SI (2) SI1174431T1 (show.php)
SK (1) SK287161B6 (show.php)
TR (1) TR200001338T2 (show.php)
TW (2) TW513431B (show.php)
UA (1) UA46166C2 (show.php)
UY (2) UY25246A1 (show.php)
WO (1) WO1999024433A1 (show.php)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DE59803108D1 (de) * 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US6777416B2 (en) 1999-12-24 2004-08-17 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
EP1244673A2 (de) * 1999-12-24 2002-10-02 Bayer Aktiengesellschaft Imidazo[1,3,5]triazinone und ihre verwendung
ES2231311T3 (es) * 1999-12-24 2005-05-16 Bayer Healthcare Ag Triazolotriazinonas y su uso.
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
AU5584901A (en) 2000-04-19 2001-10-30 Icos Corp Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2001290146A1 (en) * 2000-09-29 2002-04-08 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
AU2002226633A1 (en) 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) * 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
ES2278927T3 (es) * 2001-05-09 2007-08-16 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas de 2-(2-etoxi-5-(4-metil-piperazin-1-sulfonil)-fenil)-5-metil-7-propil-3h-imidazo(5,1-f)(1,2,4)triazin-4-ona.
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
ATE395349T1 (de) 2001-08-28 2008-05-15 Schering Corp Polycyclische guanin phosphodiesterase inhibitoren
JP2005509038A (ja) 2001-11-09 2005-04-07 シェーリング　コーポレイション 多環式グアニン誘導体ホスホジエステラーゼｖ阻害剤
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
JP4312603B2 (ja) * 2001-12-13 2009-08-12 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するピラゾロピリミジノン誘導体
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003265239A1 (en) 2002-05-22 2003-12-19 Virginia Commonwealth University Protective effects of pde-5 inhibitors
EP1506015A2 (en) * 2002-05-23 2005-02-16 Pfizer Limited Pharmaceutical combination of pde5 inhibitors with ace inhibitors
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
KR20050085563A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
ES2326808T3 (es) * 2003-04-01 2009-10-20 Smithkline Beecham Corporation Compuestos de imidazotriazina para el tratamiento de enfermedades cancerosas.
ES2326119T3 (es) 2003-04-29 2009-10-01 Pfizer Inc. 5,7-diaminopirazolo(4,3-d)pirimidinas utiles en el tratamiento de la hipertension.
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US20050079166A1 (en) 2003-05-21 2005-04-14 Alexza Molecular Delivery Corporation Self-contained heating unit and drug-supply unit employing same
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
BRPI0416202A (pt) * 2003-11-21 2006-12-26 Schering Corp formulações inibidoras de fosfodiesterase v
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
JP2007518788A (ja) 2004-01-22 2007-07-12 ファイザー・インク バソプレッシンのアンタゴニスト活性を阻害するトリアゾール誘導体
JP2007532526A (ja) * 2004-04-07 2007-11-15 ファイザー・インク ピラゾロ［４，３−ｄ］ピリミジン類
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
MX2007010142A (es) * 2005-02-18 2007-12-07 Surface Logix Inc Metodos para fabricar compuestos mejorados farmacocineticamente que comprenden residuos o grupos funcionales y composiciones farmaceuticas que comprenden dichos compuestos.
ZA200707505B (en) * 2005-02-18 2009-08-26 Surface Logix Inc Pharmacokinetically improved compounds
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
SI2366393T1 (sl) 2005-04-19 2013-12-31 Takeda Gmbh Roflumilast za zdravljenje pljučne hipertenzije
EA012577B1 (ru) 2005-05-12 2009-10-30 Пфайзер Инк. БЕЗВОДНЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ N-[1-(2-ЭТОКСИЭТИЛ)-5-(N-ЭТИЛ-N-МЕТИЛАМИНО)-7-(4-МЕТИЛПИРИДИН-2-ИЛАМИНО)-1Н-ПИРАЗОЛО[4,3-d]ПИРИМИДИН-3-КАРБОНИЛ]МЕТАНСУЛЬФОНАМИДА
US20060264624A1 (en) * 2005-05-20 2006-11-23 Alexander Heim-Riether Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1931797A2 (en) * 2005-09-29 2008-06-18 Bayer HealthCare AG Pde inhibitors and combinations thereof for the treatment of urological disorders
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
RU2008131051A (ru) * 2006-02-17 2010-03-27 Вайет (Us) Избирательное n-сульфонилирование 2-амино трифторалкильнзамещенных спиртов
US7687666B2 (en) * 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
EP2586433A1 (en) * 2006-03-17 2013-05-01 Johns Hopkins University School of Medicine N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
ATE446946T1 (de) 2006-06-27 2009-11-15 Sandoz Ag Neues verfahren zur salzherstellung
US20090298878A1 (en) * 2006-07-14 2009-12-03 Akira Matsumura Oxime compounds and the use thereof
ZA200901462B (en) * 2006-08-24 2010-07-28 Surface Logix Inc Pharmacokinetically improved compounds
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
PT2101777E (pt) 2006-12-12 2015-09-18 Gilead Sciences Inc Composição para tratar uma hipertensão pulmonar
JP5550101B2 (ja) 2007-02-12 2014-07-16 ヴィリックス ファーマシューティカルズ インコーポレイテッド トラマドールの副作用の低減薬の製造におけるトラマドールおよびｐｄｅ阻害剤の使用方法
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
WO2008100886A1 (en) * 2007-02-12 2008-08-21 Auspex Pharmaceuticals, Inc. Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (de) 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
CA2689638A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN101965348B (zh) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 伐地那非的制备方法及其中间体
ES2388371T3 (es) 2007-12-28 2012-10-15 Topharman Shanghai Co., Ltd. N-{1-[3-(2-etoxi-5-(4-etilpiperazinil)bencenosulfonil)-4,5-dihidro-5-oxo-1,2,4-triazin-6-il]etil}-butiramida, método de preparación y uso
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
US20120190849A1 (en) 2009-08-07 2012-07-26 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
CA2781799C (en) * 2009-11-27 2017-05-02 Franz-Josef Mais Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
BR112012015325A2 (pt) 2009-12-21 2018-10-23 Acef S.A. cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lingnanas e neolignanas como agente vasodilatador na terapia da disfunção erétil
PL390079A1 (pl) * 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
BR112013008140A8 (pt) 2010-09-20 2018-04-03 Envivo Pharmaceuticals Inc "compostos imidazotriazinona".
WO2012040404A1 (en) 2010-09-23 2012-03-29 Abbott Laboratories Monohydrate of an azaadamantane derivative
BR112013008983A2 (pt) 2010-10-15 2016-07-05 Gilead Sciences Inc composições e métodos de tratamento da hipertensão pulmonar
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
CN106905324B (zh) 2011-10-10 2018-09-25 H.隆德贝克有限公司 具有咪唑并吡嗪酮骨架的pde9抑制剂
AT512084A1 (de) * 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ303877B6 (cs) * 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
AP2014007820A0 (en) 2012-01-26 2014-07-31 Lundbeck & Co As H PDE9 inhibitors with imidazo triazinone backbone
CN104168895B (zh) 2012-02-28 2020-02-21 首尔制药株式会社 包含西地那非作为活性成分的掩蔽苦味的高含量快速溶解膜
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
CN105025900B (zh) 2012-12-04 2018-11-02 株式会社阿丽浱欧 包含5型磷酸二酯酶抑制剂的神经细胞的细胞凋亡抑制用组合物
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
KR20150119871A (ko) 2013-02-21 2015-10-26 아드베리오 파마 게엠베하 메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) * 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
EP3865484B1 (en) 2015-07-07 2023-11-08 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
SMT202200190T1 (it) 2015-11-16 2022-07-21 Topadur Pharma Ag Derivati del 2-fenil-3,4-diidropirrolo[2,1-f] [1,2,4]triazinone come inibitori della fosfodesterasi e loro usi
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
RU2019121646A (ru) 2016-12-14 2021-01-15 Респира Терапьютикс, Инк. Способы и композиции для лечения легочной гипертензии и других заболеваний легких
NZ758385A (en) 2017-05-22 2025-11-28 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
EP3727329A1 (en) 2017-12-20 2020-10-28 Klaria Pharma Holding AB Film formulation comprising vardenafil, method for its preparation, and use thereof
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
BR122023022641A2 (pt) 2018-05-25 2024-02-20 Imara Inc. Forma cristalina de monoidrato, composição farmacêutica compreendendo a mesma, método de inibição da atividade de pde9 em um paciente e processo para preparar a forma de monoidrato 2
US11348670B2 (en) 2018-06-14 2022-05-31 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
JP2021527267A (ja) 2018-06-14 2021-10-11 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ Ｃｇｍｐ特異的ホスホジエステラーゼ５阻害剤の薬学的組成物により勃起不全を治療するための方法
CA3110680A1 (en) 2018-08-31 2020-03-05 Imara Inc. Pde9 inhibitors for treating sickle cell disease
EP3887376A1 (en) 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
EP3939954B1 (en) 2019-03-13 2025-07-23 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
AU2021396593A1 (en) 2020-12-11 2023-07-20 Ildong Pharmaceutical Co., Ltd. Novel compounds as androgen receptor and phosphodiesterase dual inhibitor
US20240228501A1 (en) * 2021-04-21 2024-07-11 Changchun Genescience Pharmaceutical Co., Ltd. Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
CA3228160A1 (en) 2021-09-29 2023-04-06 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
IL314241A (en) 2022-03-02 2024-09-01 Topadur Pharma Ag Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
AU2024220563A1 (en) 2023-02-16 2025-08-14 University Of Rochester Improving glymphatic-lymphatic efflux

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (show.php) 1963-01-16
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
DE3166627D1 (en) 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
RU2101010C1 (ru) * 1990-04-11 1998-01-10 Дзе Апджон Компани Вкусовая маскировка ибупрофена полимерным покрытием
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
DE59803108D1 (de) 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
EP1244673A2 (de) * 1999-12-24 2002-10-02 Bayer Aktiengesellschaft Imidazo[1,3,5]triazinone und ihre verwendung
ES2278927T3 (es) 2001-05-09 2007-08-16 Bayer Healthcare Ag Nuevo uso de imidazotriazinonas de 2-(2-etoxi-5-(4-metil-piperazin-1-sulfonil)-fenil)-5-metil-7-propil-3h-imidazo(5,1-f)(1,2,4)triazin-4-ona.
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Also Published As

Publication number Publication date
NO20021714D0 (no) 2002-04-11
TWI229081B (en) 2005-03-11
EP1049695B1 (de) 2002-02-13
FI113772B (fi) 2004-06-15
IN188419B (show.php) 2002-09-21
CH693954A5 (de) 2004-05-14
ES2172945T3 (es) 2002-10-01
UA46166C2 (uk) 2002-05-15
US20060189615A1 (en) 2006-08-24
IL135462A (en) 2006-04-10
US20080113972A1 (en) 2008-05-15
TW513431B (en) 2002-12-11
EE200000291A (et) 2001-06-15
CN100430396C (zh) 2008-11-05
SK7092000A3 (en) 2001-03-12
CZ301911B6 (cs) 2010-07-28
US20050070541A1 (en) 2005-03-31
NO20021714L (no) 2000-05-11
EP1174431A3 (de) 2002-01-30
GB0010974D0 (en) 2000-06-28
ES2386420T3 (es) 2012-08-20
LU90561B1 (de) 2000-12-01
CY1112949T1 (el) 2016-04-13
US6566360B1 (en) 2003-05-20
DK1174431T3 (da) 2012-08-20
HU230154B1 (hu) 2015-09-28
SI1174431T1 (sl) 2012-09-28
US20110009367A1 (en) 2011-01-13
PE131799A1 (es) 1999-12-30
UY25246A1 (es) 2001-08-27
HUP0100394A3 (en) 2002-05-28
ES2194567A1 (es) 2003-11-16
FI20001086L (fi) 2000-05-09
DE19881732D2 (de) 2000-08-24
PT1049695E (pt) 2002-07-31
EP1049695A1 (de) 2000-11-08
PL201336B1 (pl) 2009-03-31
AU738675B2 (en) 2001-09-20
DE59803108D1 (de) 2002-03-21
ATE213246T1 (de) 2002-02-15
ES2194567B1 (es) 2005-03-01
IL163475A (en) 2015-11-30
EP1174431B1 (de) 2012-05-30
JP2002348290A (ja) 2002-12-04
EP1174431A2 (de) 2002-01-23
NO314940B1 (no) 2003-06-16
KR20010031944A (ko) 2001-04-16
PL194801B1 (pl) 2007-07-31
DE19881732C1 (de) 2002-01-31
HUP0100394A2 (hu) 2001-09-28
JP4388729B2 (ja) 2009-12-24
CA2309332C (en) 2002-12-03
US20040067945A1 (en) 2004-04-08
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
US6362178B1 (en) 2002-03-26
NO20002444D0 (no) 2000-05-11
HU227841B1 (en) 2012-05-02
DK200000766A (da) 2000-05-09
US7704999B2 (en) 2010-04-27
NO20002444L (no) 2000-05-11
US20100016323A1 (en) 2010-01-21
GB2346877A (en) 2000-08-23
CA2395558A1 (en) 1999-05-20
CA2395558C (en) 2007-07-17
GB2346877B (en) 2001-12-05
JP2001522851A (ja) 2001-11-20
WO1999024433A1 (de) 1999-05-20
CA2309332A1 (en) 1999-05-20
PL340400A1 (en) 2001-01-29
HRP20000292B1 (hr) 2008-09-30
BG65257B1 (bg) 2007-10-31
MY138535A (en) 2009-06-30
BR9812785A (pt) 2000-10-10
PT1174431E (pt) 2012-07-24
US7122540B2 (en) 2006-10-17
HN1998000175A (es) 1999-01-08
AR035972A2 (es) 2004-07-28
CU23063A3 (es) 2005-07-19
HRP20000292A2 (en) 2001-04-30
KR100430355B1 (ko) 2004-05-04
EP2295436A1 (de) 2011-03-16
US7314871B2 (en) 2008-01-01
SK287161B6 (sk) 2010-02-08
CO4980861A1 (es) 2000-11-27
CZ20001759A3 (cs) 2000-10-11
AU1558799A (en) 1999-05-31
EE04781B1 (et) 2007-02-15
CN1278822A (zh) 2001-01-03
SE522809C2 (sv) 2004-03-09
CN1508137A (zh) 2004-06-30
HRP20020585A2 (en) 2005-10-31
BR9816155B1 (pt) 2010-07-27
SI1049695T1 (en) 2002-06-30
ID25871A (id) 2000-11-09
HRP20020585B1 (hr) 2013-02-28
TR200001338T2 (tr) 2000-08-21
CN1123573C (zh) 2003-10-08
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
HU228196B1 (en) 2013-01-28
HK1031730A1 (en) 2001-06-22
SE0001745L (sv) 2000-05-11
UY25671A1 (es) 2000-03-31
JP3356428B2 (ja) 2002-12-16
DK1049695T3 (da) 2002-05-13
HK1067124A1 (zh) 2005-04-01
BG104406A (en) 2001-08-31
DK176852B1 (en) 2009-12-14
US6890922B2 (en) 2005-05-10
IL135462A0 (en) 2001-05-20
US7696206B2 (en) 2010-04-13
KR100548120B1 (ko) 2006-02-02

Similar Documents

Publication Publication Date Title
AR013759A1 (es) Imidazotriazinonas sustituidas por 2-fenilo, procedimiento para su preparacion, medicamentos que los contienen y el uso de dichos compuestos para la elaboracion de medicamentos
AR016131A1 (es) -oxazolidinonas triciclicamente substituidas, procedimientos para su preparacion, uso de dichos compuestos y medicamentos.
ES8704473A1 (es) Procedimiento para la produccion de derivados de la 13-beta-milbemicina
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
ES2002254A4 (es) Nuevos 5-alcoxi-2,4-diamino-alquilbenzenos asi como tintes para el cabello con 5-alcoxi-2,4-diamino-alquil-benzenos.
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
AR020165A1 (es) Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos
ES2052640T3 (es) Procedimiento para la obtencion de oxazolidinonas.
ES2189365T3 (es) Nuevos derivados de eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
ES2065755T3 (es) Derivados de 3-aminopiridacinas activos sobre el sistema nervioso central.
ES2013664A6 (es) Un procedimiento para preparar derivados de nucleosidos de aciclopiramidina sustituidos en la posicion 6.
CO4900071A1 (es) Derivados de pirido [4´, 3´:4,5] tieno (2,3- d) pirimidina sustituidos en posicion 3
ECSP034838A (es) Inmunoconjugados del anticuerpo cd44 citotoxico
ES2060583T3 (es) Nuevos derivados de cefalosporina, procedimiento para su obtencion y preparados farmaceuticos correspondientes.
ES2126581T3 (es) Derivados de 3-(piperazino-alquil)indol condensados en posiciones 1,7, asi como procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
ES484327A1 (es) Procedimiento para la obtencion de 2-imino-1,3-tiaza-ciclo- alcanos
ES2102043T3 (es) Derivados de 22-en-25-oxa en la serie de la vitamina d, procedimiento para su preparacion, preparados farmaceuticos que los contienen, asi como su utilizacion en calidad de medicamentos.
ES2096396T3 (es) Procedimiento para la obtencion de polimeros, formados por alqu-1-enos con 2 a 10 atomos de carbono con empleo de complejos de metaloceno racemicos como catalizadores.
ES2063117T3 (es) Derivados del tieno(2,3-d)acepina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2095848T3 (es) Nuevos derivados de fosfolipidos y su utilizacion para la preparacion de medicamentos antiviricos.
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
CO5011071A1 (es) Inhibicion de las metaloproteinasas de matriz por acidos 2-(w/aroilalquil)-4-biaril-4-oxobutiricos y composiciones farmaceuticas que los contienen
ES2035452T3 (es) Procedimiento para la obtencion conjunta de 3-dialquil-aminopropionitrilos, bis-(2-cianoetil)-eteres y en caso deseado etilencianhidrina.
ES2183434T3 (es) Derivados de cromano sustituidos con carboxilo utiles como agonistas de adrenoreceptores.
ES471689A1 (es) Procedimiento para la obtencion de derivados benz-aciloben- zimidazol-2-carboxilicos.

Legal Events

Date Code Title Description
FG Grant, registration